Breaking News, Promotions & Moves

OXiGENE Appoints President and CEO

Chaplin brings extensive R&D experience in the field oncology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

David (Dai) Chaplin, Ph.D., has been appointed president and chief executive officer of OXiGENE, Inc., replacing Peter Langecker, M.D., Ph.D. Dr. Chaplin, a current member of OXiGENE’s board, brings extensive experience in the fields of oncology research and cancer drug development.   Dr. Chaplin has served as a senior member of management teams for several biopharma companies. His research in the area of vascular disrupting strategies resulted in the identification of Combretastatin A4P (...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters